Rohit Gosain

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating novel uses of oral selective estrogen receptor degraders (SERDs), including elacestrant, highlighting trials exploring its combination with other therapies and its potential in different patient populations.

Along with the Oncology Brothers, Paolo Tarantino, MD, shares insights on what has been learned about proactive monitoring and management of adverse reactions effects (AEs) to elacestrant, emphasizing strategies to help patients remain on therapy while maximizing their quality of life.

Panelists discuss how ongoing trials may reshape the treatment landscape for HER2-altered NSCLC, particularly regarding the roles of ADCs and TKIs in managing both HER2-mutated and HER2-overexpressing NSCLC.

In a recent Treatment Algorithms with the Oncology Brothers program, Rohit Gosain, MD, Rahul Gosain, MD, and Shannon N.

Panelists discuss how ongoing trials may reshape the treatment landscape for HER2-altered NSCLC, particularly regarding the roles of ADCs and TKIs in managing both HER2-mutated and HER2-overexpressing NSCLC.

Surgery followed by platinum-based chemotherapy may provide the most benefit for patients with ovarian cancer, according to a medical oncologist.

Panelists discuss how thoracic oncologists are adapting to a rapidly evolving treatment landscape for lung cancer, focusing on the integration of novel therapies and the importance of biomarker-driven approaches in patient care.

With the Oncology Brothers, Uma Borate, MD, discusses how ziftomenib is showing promising results as a targeted therapy for NPM1-mutated and KMT2A-rearranged acute myeloid leukemia (AML) in the ongoing KOMET-007 trial, offering potential new treatment options for this challenging patient population.

With the Oncology Brothers, Uma Borate, MD, discusses how the combination of venetoclax with an IDH1 inhibitor and 7+3 chemotherapy leads to higher remission rates and MRD negativity in IDH1-mutated AML, offering a promising treatment option for these patients.

Experts review the 5-year results of the phase 3 SEQUOIA trial evaluating treatment options for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma at the 66th American Society of Hematology Annual Meeting and Exposition 2024.